Alector, Inc. (NASDAQ:ALEC) insider Robert Paul sold 30,000 shares of the firm's stock in a transaction dated Tuesday, June 15th. The shares were sold at an average price of $22.07, for a total value of $662,100.00. Following the completion of the sale, the insider now directly owns 290,819 shares in the company, valued at $6,418,375.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Robert Paul also recently made the following trade(s):
- On Tuesday, June 8th, Robert Paul sold 19,175 shares of Alector stock. The shares were sold at an average price of $19.18, for a total transaction of $367,776.50.
- On Friday, May 21st, Robert Paul sold 14,975 shares of Alector stock. The shares were sold at an average price of $18.14, for a total transaction of $271,646.50.
- On Tuesday, May 18th, Robert Paul sold 4,200 shares of Alector stock. The shares were sold at an average price of $18.04, for a total transaction of $75,768.00.
- On Wednesday, April 7th, Robert Paul sold 22,300 shares of Alector stock. The shares were sold at an average price of $19.20, for a total transaction of $428,160.00.
- On Tuesday, March 23rd, Robert Paul sold 13,800 shares of Alector stock. The shares were sold at an average price of $22.21, for a total transaction of $306,498.00.
ALEC traded up $0.93 during midday trading on Monday, reaching $22.16. 18,828 shares of the company's stock were exchanged, compared to its average volume of 615,960. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -8.71 and a beta of 1.03. Alector, Inc. has a one year low of $9.12 and a one year high of $33.82. The company's 50-day moving average is $18.42.
Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Tuesday, May 4th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. Alector had a negative net margin of 1,122.03% and a negative return on equity of 69.73%. On average, equities research analysts anticipate that Alector, Inc. will post -2.82 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Alector by 2.9% in the first quarter. BNP Paribas Arbitrage SA now owns 23,252 shares of the company's stock valued at $468,000 after acquiring an additional 664 shares during the last quarter. US Bancorp DE raised its stake in shares of Alector by 68.5% in the first quarter. US Bancorp DE now owns 1,968 shares of the company's stock valued at $40,000 after acquiring an additional 800 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Alector by 3.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 29,075 shares of the company's stock valued at $440,000 after acquiring an additional 836 shares during the last quarter. Swiss National Bank raised its stake in shares of Alector by 1.1% in the first quarter. Swiss National Bank now owns 99,600 shares of the company's stock valued at $2,006,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Penserra Capital Management LLC raised its stake in shares of Alector by 172.2% in the fourth quarter. Penserra Capital Management LLC now owns 1,840 shares of the company's stock valued at $27,000 after acquiring an additional 1,164 shares during the last quarter. Institutional investors own 57.64% of the company's stock.
Several equities research analysts recently weighed in on ALEC shares. Morgan Stanley increased their target price on shares of Alector from $31.00 to $33.00 and gave the company an "overweight" rating in a research note on Monday, April 19th. Zacks Investment Research cut shares of Alector from a "hold" rating to a "sell" rating in a research note on Wednesday, April 28th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of "Buy" and an average price target of $34.40.
Alector Company Profile
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Further Reading: Cost of Equity
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What Is an EV Stock?7 Great Dividend Stocks to Buy For a Comfortable Retirement
There are people who will say the day of set it and forget it retirement accounts are over. But it’s a narrative we’ve heard before. The truth is the formula for saving for and enjoying a comfortable retirement, like the formula for weight loss, hasn’t really changed. A lot depends on whether an individual has the discipline to see it through.
Dividend stocks remain one of the core elements of a retirement portfolio. As individuals near retirement the ability to reinvest dividends allows for a greater total return. And once individuals need to live off their portfolio, the dividends provide a source of income without having to tap their principal.
However, not all dividend stocks are the same and many investors get sucked in by the allure of a high-yield dividend stock. But what you’re really looking for are companies with a history of increasing its dividend. The ability to increase a dividend over time illustrates that the company has a business model that can hold up regardless of how the broader economy is performing.
In this special presentation, we’ll highlight seven stocks that individuals can buy today to capture a stable, recurring dividend.
View the "7 Great Dividend Stocks to Buy For a Comfortable Retirement"